Loading...
  • graft versus
  • I. To investigate how donor killer-cell immunoglobulin-like receptors (KIR) genes of interest (activating KIR2DS2 and 2DS4, inhibitory KIR2DL1, 2DL2/2DL3, 3DL1, 3DL2), together with their recipient ligands where known, influence CMV reactivation-free survival after allogeneic HCT, independently of clinical risk factors such as onset of acute graft-versus-host disease. (clinicaltrials.gov)
  • patients
  • We summarized recent genetic data that may guide future efforts towards implementing risk-adapted therapy based on mutational profile and improving disease control and survival of affected patients. (readbyqxmd.com)
  • Lymphoma
  • This study was funded by the Leukemia & Lymphoma Society, The V Foundation, William Lawrence & Blanche Hughes Foundation, Gabrielle's Angel Foundation and the Howard Hughes Medical Institute. (healthcanal.com)
  • antibodies
  • Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. (bioportfolio.com)
  • Cell surface molecules aberrantly expressed or overexpressed by myeloid leukemic cells represent potential disease-specific therapeutic targets for antibodies. (bioportfolio.com)
  • Antinuclear antibodies, anti-neutrophilic cytoplasmatic antibodies, and cryoglobulins were not detected. (dovepress.com)
  • Molecular
  • They are distinguished from each other based on numbers and types of leukemia cells in the blood, appearance of leukemia cells in the blood and bone marrow cells and cytogenetic and molecular abnormalities including absence of t(9:22) and BCR/ABL1 and rearrangement of platelet-derived growth factor receptor, alpha polypeptide (PDGFRA), platelet-derived growth factor receptor, beta polypeptide (PDGFRB) or fibroblast growth factor receptor 1 (FGFR1). (biomedcentral.com)
  • Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)," Blood , vol. 88, no. 7, pp. 2410-2414, 1996. (hindawi.com)
  • Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring," Case Reports in Hematology , vol. 2012, Article ID 458716, 3 pages, 2012. (hindawi.com)
  • Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response totreatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients," Experimental Hematology , vol. 41, no. 5, pp. 424-431, 2013. (hindawi.com)
  • The e1a3 and e1a2 (p190) transcripts have been reported to have a similar molecular weight and probably a similar clinical profile, thus in these cases the presence of e1a3 was associated with extramedullary infiltration and disease acceleration. (biomedcentral.com)
  • myeloma
  • Multiple myeloma with Extra medullary disease: Impact of Autologous stem cell transplantation on outcome. (aiims.edu)
  • Patients with smoldering multiple myeloma (SMM) have a higher degree of disease involvement, characterized by an increase in the serum M-protein and a higher percentage of clonal plasma cells in the marrow. (renalandurologynews.com)
  • distinguish
  • Important genetic abnormalities have been identified which help to distinguish between these diseases. (biomedcentral.com)
  • This discovery is promising for patients as it will aid in diagnosing these cancers, which are currently difficult for physicians to distinguish from other leukemias. (healthcanal.com)
  • Tyner
  • It will accelerate our ability to tailor treatments to individuals and each research victory gives us more insight into the nature of this complex disease," said Jeffrey W. Tyner, Ph.D. , an assistant professor with the OHSU Knight Cancer Institute and Cell & Developmental Biology Department, whose lab led the research. (healthcanal.com)
  • bone
  • These diseases share several characteristics including an enlarged liver and spleen, an increased WBC and a hyper-cellular bone marrow. (biomedcentral.com)